Share
   
Title
Co-Chairs' Choice
Code
OAXLB01
Session Type
Oral abstract session

OAXLB0101 HPTN083 interim results: Pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM,TGW)
Abstract

OAXLB0102 Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana
Abstract

OAXLB0103 Community HIV testing continuity in the context of COVID-19 lockdown and social distancing
Abstract

OAXLB0104 The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection
Simiso mandisa Sokhela, University of the Witwatersrand, South Africa
Abstract

OAXLB0105 The first long-term remission of chronic HIV-1 infection without myeloablation?
Abstract

OAXLB0106 Western Cape: COVID-19 and HIV / Tuberculosis
Mary-ann Davies, University of Cape Town, South Africa